St. Paul and the Foundry Team Up

Combining the resources and skills of an incubator and venture fund, with contacts in two of the most important medical device communities, Minneapolis-based St. Paul Ventures and West Coast-based The Foundry are joining forces.

Combining the resources and skills of an incubator and venture fund, with contacts in two of the most important medical device communities, Minneapolis-based St. Paul Ventures and West Coast-based The Foundry are joining forces, as St. Paul becomes an investor in The Foundry and Allan Will, founder of the incubator, joins the venture firm as a general partner. St. Paul recently raised a new $1 billion fund, of which one-quarter of the proceeds will go to health care, and 80% of its health care investments will be in medical devices.

For St. Paul partner David Stassen, the partnership with Will was a long time coming. Stassen, who joined St. Paul...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Inaccurate Carbon Dioxide Readings Prompt Class I Recall Of Draeger Ventilation Filters

 

Draeger Medical has recalled certain SafeStar and TwinStar ventilation filters after reports of serious injuries caused by misleading carbon dioxide readings.

After Thought-Control Demo, Synchron Plans Pilot Study With Upgraded BCI On Path To Pivotal Trial

 
• By 

Synchron is preparing a pilot study of its fully wireless, second-gen brain-computer interface after an ALS patient controlled an iPad solely by thought. If all goes as planned, Synchron’s BCI will move into pivotal trials in 2026.

Apreo Health Raises $130M, First Patient Treated In US Clinical Trial

 

Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.